Additionally, in prostate cancer patients treated with ipilimumab, a high expression of VISTA has been observed, indicating that the combined blockade of CTLA-4 and VISTA presents a promising strategy for enhancing anti-tumor efficacy (163). The gene discussed is VSIR; the disease is prostate carcinoma.